IDEXX Laboratories, Inc. $IDXX Stock Acquired by Titan Investment Management LLC

Titan Investment Management LLC increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,205 shares of the company’s stock after buying an additional 1,509 shares during the period. IDEXX Laboratories accounts for approximately 1.6% of Titan Investment Management LLC’s holdings, making the stock its 22nd biggest holding. Titan Investment Management LLC’s holdings in IDEXX Laboratories were worth $2,196,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Howland Capital Management LLC raised its stake in shares of IDEXX Laboratories by 0.8% in the third quarter. Howland Capital Management LLC now owns 47,172 shares of the company’s stock worth $24,633,000 after acquiring an additional 396 shares during the last quarter. NBT Bank N.A. acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $280,000. Root Financial Partners LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $72,000. Cardinal Capital Management increased its holdings in shares of IDEXX Laboratories by 5.6% in the third quarter. Cardinal Capital Management now owns 14,949 shares of the company’s stock valued at $7,806,000 after purchasing an additional 798 shares in the last quarter. Finally, Crossmark Global Holdings Inc. raised its position in IDEXX Laboratories by 2.2% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 7,177 shares of the company’s stock worth $3,748,000 after purchasing an additional 155 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 2.4%

NASDAQ:IDXX opened at $566.76 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98. The business’s 50-day moving average price is $532.51 and its two-hundred day moving average price is $551.58. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $44.65 billion, a price-to-earnings ratio of 39.86, a PEG ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company earned $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.79% of the stock is owned by insiders.

Analysts Set New Price Targets

IDXX has been the subject of several research analyst reports. The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They issued a “buy” rating and a $740.00 price objective for the company. KeyCorp began coverage on IDEXX Laboratories in a research report on Monday, October 12th. They issued a “sector weight” rating on the stock. JPMorgan Chase & Co. lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research note on Friday, October 16th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, UBS Group boosted their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Seven analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $744.09.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.